Lymphoma

Lymphoma

As part of Taussig Cancer Institute's mission to improve patient outcomes, lymphoma program staff constantly update and review standard-of-care treatments, participate in clinical trials of new treatment strategies, and work closely with the blood and marrow transplant program. The results of this carefully coordinated approach are reflected in the outcomes shown in the survival curves included here.

Five-Year Overall Survival of Patients With Aggressive Non-Hodgkin Lymphoma by Disease Type (N = 1294)

2008-2018

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Burkitt Lymphoma (N = 61) 38 32 25 20 11
DLBCL (N = 1068) 743 554 413 312 202
Mantle Cell (N = 165) 138 106 89 64 45

DLBCL = diffuse large B-cell lymphoma

Five-Year Overall Survival of Patients With Follicular Versus Other Types of Indolent Lymphomaᵃ (N = 989)

2008-2018

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Follicular (N = 426) 356 283 219 164 105
Nonfollicular (N = 563) 467 392 301 233 157

ᵃIncludes Waldenstoms macroglobulinemia, lymphoplasmacytic, marginal b-cell, splenic marginal b cell, cutaneous t-cell

Five-Year Overall Survival of Patients With Hodgkin Lymphoma (N = 447)

2008-2018

Five-Year Overall Survival of Patients With Chronic Lymphocytic Leukemiaᵃ (N = 500)

2008-2018

ᵃB-cell chronic lymphocytic leukemia/small lymphocytic lymphoma